Human Platelet Lysate Industry: Demand, Growth and Outlook Through 2035

Why Human Platelet Lysate Is Gaining Attention

Human platelet lysate is derived from human platelet concentrates and contains growth factors, cytokines, and other bioactive components that support cell growth and proliferation. Unlike fetal bovine serum, HPL provides a human-derived, xeno-free alternative that can be useful in clinical and research environments.

Its adoption is particularly strong in mesenchymal stem cell expansion, cell therapy development, regenerative medicine, tissue engineering, and biopharmaceutical production. As therapies move from laboratory research toward clinical applications, the need for standardized, GMP-compliant and reproducible cell culture supplements is becoming more important.

Cell Therapy Is Creating New Demand

Cell therapy and regenerative medicine accounted for approximately 47% of revenue in 2025, making this the leading application segment.

The growing pipeline of stem cell therapies is creating demand for culture supplements that can support cell expansion while reducing concerns associated with animal-derived components. HPL is being explored across applications such as bone regeneration, tendon repair, nerve regeneration and other tissue-repair approaches.

Biotechnology and pharmaceutical companies also represented the leading end-user group, accounting for approximately 42% of revenue in 2025. Their use of HPL spans research, diagnostics, cell manufacturing, immunotherapy and biopharmaceutical development.

Pooled HPL Remains the Preferred Type

Pooled human platelet lysate accounted for approximately 58% of revenue in 2025. Pooling platelet units can provide a more consistent combination of growth factors and cytokines, making it suitable for cell culture applications.

At the same time, pathogen-inactivated platelet lysate is expected to record the fastest growth. Advances in pathogen-reduction technologies are improving safety by targeting bacteria, viruses and other potential contaminants while supporting the development of clinical-grade products.

Europe Leads While Asia-Pacific Accelerates

Europe accounted for approximately 41% of revenue in 2025, supported by its strong biomedical research ecosystem, established regenerative medicine sector and regulatory focus on cell-based therapies.

Germany is particularly important because of its well-developed biotechnology ecosystem and research hubs in cities such as Munich, Berlin and Heidelberg.

Meanwhile, Asia-Pacific is expected to record the fastest growth through 2035. Increasing healthcare expenditure, expanding biotechnology capabilities, government support for regenerative medicine and rising chronic disease burdens are creating favorable conditions for HPL adoption.

China is a major contributor to regional growth, while India, Japan and other emerging biotechnology hubs are also developing their cell therapy and advanced healthcare capabilities.

Innovation Is Moving Toward GMP and Xeno-Free Solutions

One of the most important developments in this field is the shift toward GMP-grade, standardized and xeno-free products.

Companies are investing in improved production processes, quality control and scalable manufacturing systems to support the transition from laboratory research to clinical applications. This is especially relevant as cell and gene therapy developers require reliable raw materials that can meet increasingly demanding regulatory expectations.

AI can also contribute indirectly by improving cell-culture process optimization, demand forecasting, quality inspection and manufacturing consistency. As biomanufacturing becomes more automated, data-driven production could help manufacturers improve reproducibility and reduce production variability.

Key Companies Driving Innovation

Several companies are contributing to the development and commercialization of human platelet lysate products, including Merck KGaA, STEMCELL Technologies, Macopharma, Compass Biomedical, Mill Creek Life Sciences, Cook Regentec, PL BioScience, Sartorius, Thermo Fisher Scientific and Corning.

Recent developments also show increasing activity in product availability and clinical-grade solutions. Compass Biomedical's HPL products became available through the Captivate Bio Access Program in 2025, while PL BioScience introduced its ELAREM Ultimate-FD PLUS product, a gamma-irradiated GMP-grade HPL manufactured in Germany.